Wu Ya-Qi, Luo Lu-Yao, Tang Ya-Nan, Li Hu-Jun, Li Yan-Jie, Wang Ying, Yao Yao, Li De-Peng, Xu Kai-Lin, Li Zhen-Yu
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Aug;28(4):1228-1233. doi: 10.19746/j.cnki.issn.1009-2137.2020.04.024.
To investigate the expression and clinical significant of VCAN and its related molecules in patients with MM.
Ficoll density gradient centrifugation method was used to speared the bone marrow mononuclear cell in 25 cases of MM before and after treatment, the relative mRNA expression of VCAN and their related molecules (FAK, FN, MK, and HAS) in bone marrow was detected by real-time quantitative PCR, and their protein expression was determined by Western bolt.
The expression of VCAN, FK and FN in the effective group after treatment was significantly lower than that before treatment (P＜0.05), however, the expression of MK and HAS showed no statistically significantly different before and after treatment (P＜0.05). The expression of VCAN of patients in non remission group was significantly higher than that in control group (P＜0.05). The expression of FAK and FN of patients in no remission group was significant increased as compared with the patients in newly diagnosed group (P＜0.05). The relative expression of VCAN mRNA in the patients at 3rd stage was significantly higher than those at the 1st stage (P＜0.05) and control group but showed no significant difference to the patients at 2nd stage (P＜0.05). The expression of VCAN and its related proteins (FAK, MK, FN) showed positively correlation in bone marrow mononuclear cells of MM patients (P＜0.05). The correlation between VCAN and HAS was not statistically significant (r=0.259，P＞0.05). Survival analysis showed that the relative expression of VCAN mRNA was associated with OS (P=0.049) and PFS (P=0.041) in MM patients.
VCAN and its related molecules are highly expressed in MM patients; VCAN may act as potential biomarker in the development of multiple myeloma.
探讨硫酸软骨素蛋白聚糖（VCAN）及其相关分子在多发性骨髓瘤（MM）患者中的表达及临床意义。
采用Ficoll密度梯度离心法分离25例MM患者治疗前后的骨髓单个核细胞，采用实时定量聚合酶链反应（PCR）检测骨髓中VCAN及其相关分子（黏着斑激酶（FAK）、纤连蛋白（FN）、基质金属蛋白酶（MK）和透明质酸合酶（HAS））的相对mRNA表达，并采用蛋白质免疫印迹法检测其蛋白表达。
治疗后有效组VCAN、FK和FN的表达明显低于治疗前（P＜0.05），然而，MK和HAS的表达在治疗前后差异无统计学意义（P＜0.05）。未缓解组患者VCAN的表达明显高于对照组（P＜0.05）。未缓解组患者FAK和FN的表达与新诊断组患者相比明显升高（P＜0.05）。Ⅲ期患者VCAN mRNA的相对表达明显高于Ⅰ期患者（P＜0.05）和对照组，但与Ⅱ期患者相比差异无统计学意义（P＜0.05）。MM患者骨髓单个核细胞中VCAN及其相关蛋白（FAK、MK、FN）的表达呈正相关（P＜0.05）。VCAN与HAS之间的相关性无统计学意义（r = 0.259，P＞0.05）。生存分析表明，MM患者中VCAN mRNA的相对表达与总生存期（OS）（P = 0.049）和无进展生存期（PFS）（P = 0.041）相关。
VCAN及其相关分子在MM患者中高表达；VCAN可能是多发性骨髓瘤发生发展的潜在生物标志物。
